Zhende Medical Co., Ltd. (603301.SS)
CNY 22.69
(-0.26%)
CNY 22.69
(-0.26%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 452.1 Million | 1.24 Billion | 817.62 Million | 3.12 Billion | 197.76 Million | 20.24 Million |
| Net Income | 213.39 Million | 703.01 Million | 720.94 Million | 2.97 Billion | 176.58 Million | 129.87 Million |
| Depreciation & Amortization | 242.96 Million | 194.27 Million | 141.96 Million | 78.56 Million | 65.29 Million | 61.5 Million |
| Deferred income taxes | -28.6 Million | -6.2 Million | -16.22 Million | -18.95 Million | -65.32 Thousand | 932.7 Thousand |
| Stock-based compensation | 5.22 Million | 19.6 Million | 14.52 Million | - | - | - |
| Change in working capital | -270.12 Million | 145.02 Million | -114.4 Million | -150.91 Million | -77.19 Million | -198.82 Million |
| Other non-cash items | 18.5 Million | 203.72 Million | 70.81 Million | 221.28 Million | 33.08 Million | 27.68 Million |
| Investing Cash Flow | -1.05 Billion | -992.79 Million | -554.41 Million | -1.79 Billion | -319.08 Million | -161.62 Million |
| Investments in PPE | -599.23 Million | -754.12 Million | -695.46 Million | -1.09 Billion | -273.78 Million | -226.7 Million |
| Acquisitions | -311.91 Million | -25.52 Million | -545.53 Million | -92.33 Million | -33.2 Million | -16.31 Million |
| Investment purchases | -569.87 Million | -302.77 Million | -575.65 Million | -1.31 Billion | -233 Million | -714 Million |
| Sales/Maturities of investments | 410.62 Million | 86.45 Million | 1.02 Billion | 872.07 Million | 217.56 Million | 719.54 Million |
| Other Investing Activities | -70 Thousand | 3.16 Million | 241.3 Million | -163.13 Million | 3.34 Million | 75.85 Million |
| Financing Cash Flow | -423.28 Million | 455.99 Million | -379.56 Million | -277.65 Million | 428.15 Million | 349.27 Million |
| Debt repayment | -110 Thousand | -1.97 Billion | -533 Million | -892.1 Million | -865.7 Million | -715.95 Million |
| Dividends payments | -399.48 Million | -136.32 Million | -522.57 Million | -60.2 Million | -35 Million | -21.01 Million |
| Common Stock Repurchased | - | -113.15 Million | -133.38 Million | - | - | - |
| Common Stock Issuance | - | 113.15 Million | 133.38 Million | - | - | -21.96 Million |
| Other Financing Activities | 322.56 Thousand | 2.59 Billion | 697.08 Million | 692.74 Million | 1.35 Billion | 1.08 Billion |
| Accounts receivables | 307.44 Million | -127.95 Million | 49.7 Million | -468.07 Million | -150.94 Million | -81.94 Million |
| Accounts payables | -536.27 Million | 507.89 Million | -426.95 Million | 995.43 Million | 121.16 Million | 56.11 Million |
| Inventory | -12.69 Million | -228.7 Million | 279.07 Million | -659.32 Million | -47.35 Million | -173.92 Million |
| Other working capital | 5.22 Million | -6.2 Million | -16.22 Million | -18.95 Million | -65.32 Thousand | -24.89 Million |
| Cash at beginning of period | 2.06 Billion | 1.35 Billion | 1.5 Billion | 553.36 Million | 242.17 Million | 47.65 Million |
| Cash at end of period | 1.04 Billion | 2.06 Billion | 1.35 Billion | 1.5 Billion | 553.36 Million | 242.17 Million |
| Capital Expenditure | -599.23 Million | -754.12 Million | -695.46 Million | -1.09 Billion | -273.78 Million | -226.7 Million |
| Effect of forex changes on cash | 12.81 Million | -3.69 Million | -38.29 Million | -96.65 Million | 4.36 Million | -13.36 Million |
| Net cash flow / Change in cash | -1.01 Billion | 705.55 Million | -154.64 Million | 956.34 Million | 311.18 Million | 194.52 Million |
| Free Cash Flow | -147.12 Million | 491.92 Million | 122.16 Million | 2.02 Billion | -76.02 Million | -206.45 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 146.35 Million | 87.71 Million | 73.39 Million | 213.39 Million | -102.12 Million | 63.15 Million |
| Depreciation & Amortization | - | 69.46 Million | 69.46 Million | 242.96 Million | 242.96 Million | -115.17 Million |
| Deferred income taxes | - | - | - | -28.6 Million | - | 147.91 Million |
| Stock-based compensation | - | - | - | 5.22 Million | 5.22 Million | -20.95 Million |
| Change in working capital | - | -258.68 Million | - | -270.12 Million | 299.97 Million | -11.78 Million |
| Other non-cash items | -93.31 Million | 72.27 Million | -47.1 Million | 18.5 Million | -251.56 Million | 73.13 Million |
| Investing Cash Flow | -189.04 Million | -249.73 Million | -210.62 Million | -1.05 Billion | -2.62 Million | -210.65 Million |
| Investments in PPE | -189.04 Million | -145.17 Million | -161.46 Million | -599.23 Million | -228.39 Million | -129.85 Million |
| Acquisitions | 50 Million | 310.06 Thousand | -48.66 Million | -311.91 Million | 396.1 Thousand | -72.99 Million |
| Investment purchases | -250 Million | -354.86 Million | -501.5 Thousand | -569.87 Million | -95.11 Million | -7.82 Million |
| Sales/Maturities of investments | 200 Million | 250 Million | - | 410.62 Million | 308.18 Million | - |
| Other Investing Activities | - | -101.57 Million | -501.5 Thousand | -70 Thousand | 225.37 Million | 13.5 Thousand |
| Financing Cash Flow | -140.98 Million | -322.84 Million | 698.23 Million | -423.28 Million | -348.97 Million | -355.55 Million |
| Debt repayment | -3.5 Million | -316 Million | -727.76 Million | -110 Thousand | -130.5 Million | -359 Million |
| Dividends payments | - | -7.85 Million | -6.84 Million | -399.48 Million | -399.48 Million | -5.92 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -137.48 Million | -5.9 Million | -22.58 Million | 322.56 Thousand | -17.13 Million | 9.37 Million |
| Accounts receivables | - | -256.36 Million | - | 307.44 Million | 307.44 Million | 13.69 Million |
| Accounts payables | - | - | - | -536.27 Million | - | 17.66 Million |
| Inventory | - | -2.32 Million | - | -12.69 Million | -12.69 Million | -25.47 Million |
| Other working capital | - | - | - | 5.22 Million | 5.22 Million | -17.66 Million |
| Cash at beginning of period | 1.1 Billion | 1.58 Billion | 1.04 Billion | 2.06 Billion | 1.2 Billion | 1.64 Billion |
| Cash at end of period | 806.65 Million | 1.1 Billion | 1.56 Billion | 1.04 Billion | 1.04 Billion | 1.2 Billion |
| Capital Expenditure | -189.04 Million | -145.17 Million | -161.46 Million | -599.23 Million | -228.39 Million | -129.85 Million |
| Effect of forex changes on cash | - | 2.18 Million | 11.06 Million | 12.81 Million | 1.12 Million | -9.2 Million |
| Net cash flow / Change in cash | -298.29 Million | -478.15 Million | 524.97 Million | -1.01 Billion | -161.21 Million | -439.12 Million |
| Free Cash Flow | -136.01 Million | -54.65 Million | -135.16 Million | -147.12 Million | -39.13 Million | 6.43 Million |
INDORAMA
IBM
ABCP
PMDRF
ENLAY
VO2